Tag
The discontinuation of Biogen’s Aduhelm is a cautionary tale of overpromising, under-delivering, and an inside look at FDA sausage-making.
The FDA granted full clinical approval to Leqembi (lecanemab) on Thursday, July 6, making it only the second new drug…